{"product_id":"rad-140-lgd-4033-yk-11","title":"RAD-140 + LGD-4033 + YK-11","description":"\u003cdiv class=\"qMYqUG_convSearchResultHighlightRoot\"\u003e\n\u003cdiv class=\"\"\u003e\n\u003csection class=\"text-token-text-primary w-full focus:outline-none has-data-writing-block:pointer-events-none [\u0026amp;:has([data-writing-block])\u0026gt;*]:pointer-events-auto R6Vx5W_threadScrollVars scroll-mb-[calc(var(--scroll-root-safe-area-inset-bottom,0px)+var(--thread-response-height))] scroll-mt-[calc(var(--header-height)+min(200px,max(70px,20svh)))]\" dir=\"auto\"\u003e\n\u003cdiv class=\"text-base my-auto mx-auto pb-8 [--thread-content-margin:var(--thread-content-margin-xs,calc(var(--spacing)*4))] @w-sm\/main:[--thread-content-margin:var(--thread-content-margin-sm,calc(var(--spacing)*6))] @w-lg\/main:[--thread-content-margin:var(--thread-content-margin-lg,calc(var(--spacing)*16))] px-(--thread-content-margin)\"\u003e\n\u003cdiv class=\"[--thread-content-max-width:40rem] @w-lg\/main:[--thread-content-max-width:48rem] mx-auto max-w-(--thread-content-max-width) flex-1 group\/turn-messages focus-visible:outline-hidden relative flex w-full min-w-0 flex-col agent-turn\"\u003e\n\u003cdiv class=\"flex max-w-full flex-col gap-4 grow\"\u003e\n\u003cdiv dir=\"auto\" class=\"min-h-8 text-message relative flex w-full flex-col items-end gap-2 text-start break-words whitespace-normal outline-none keyboard-focused:focus-ring [.text-message+\u0026amp;]:mt-1\" tabindex=\"0\"\u003e\n\u003cdiv class=\"flex w-full flex-col gap-1 empty:hidden\"\u003e\n\u003cdiv class=\"markdown prose dark:prose-invert wrap-break-word w-full dark markdown-new-styling\"\u003e\n\u003ch2 class=\"PDq2pG_selectionAnchorContainer\"\u003eRAD-140 (Testolone) + LGD-4033 (Ligandrol) + YK-11 (Myostine) | SARMs Research UK\u003cspan class=\"PDq2pG_selectionAnchor\"\u003e\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003ch2\u003eAdvanced Myogenic Signalling Research Set\u003c\/h2\u003e\n\u003cp\u003eThe BioPlex Advanced Myogenic Signalling Research Set combines RAD-140 (Testolone) 50×15mg, LGD-4033 (Ligandrol) 50×15mg and YK-11 (Myostine) 50×15mg, providing three individually identified research compounds within a structured triple-compound format. The combination is centred on androgen-receptor biology, tissue-selective signalling and experimental investigation of molecular pathways associated with myogenic regulation.\u003c\/p\u003e\n\u003cp\u003eRAD-140 and LGD-4033 are non-steroidal selective androgen receptor modulators developed for investigation of androgen-receptor activity and tissue-selective responses. Although both interact with the same broad receptor system, differences in molecular structure and experimental history mean they should be treated as separate research compounds rather than pharmacologically interchangeable molecules.\u003c\/p\u003e\n\u003cp\u003eYK-11 introduces a substantially different element. It is frequently grouped commercially with SARMs because of its androgen-receptor-associated activity, but its steroidal structure distinguishes it from conventional non-steroidal SARMs such as RAD-140 and LGD-4033. Experimental interest in YK-11 has also extended into myogenic differentiation and follistatin-associated signalling, although its direct evidence base remains considerably more limited.\u003c\/p\u003e\n\u003cp\u003eThe Advanced Myogenic Signalling Research Set therefore brings together three compounds associated with overlapping but distinguishable areas of androgen and myogenic research.\u003c\/p\u003e\n\u003cp\u003eThe set name reflects this laboratory research theme rather than establishing a predetermined combined response. Myogenic regulation involves complex interactions between receptor signalling, transcription factors, regulatory proteins and cellular conditions.\u003c\/p\u003e\n\u003cp\u003eBy presenting all three compounds together while retaining their individual identities, BioPlex provides a comparative research format for examining conventional selective androgen-receptor modulation alongside the more specialised experimental questions associated with YK-11.\u003c\/p\u003e\n\u003ch2\u003e\u003c\/h2\u003e\n\u003ch2\u003eHow RAD-140, LGD-4033 and YK-11 Work Together\u003c\/h2\u003e\n\u003cp\u003eRAD-140, LGD-4033 and YK-11 share an important connection through androgen-receptor-associated research, but the scientific value of the triple set comes from their differences as much as their similarities. The androgen receptor is a ligand-responsive nuclear receptor capable of influencing gene transcription following interaction with suitable molecules.\u003c\/p\u003e\n\u003cp\u003eRAD-140 and LGD-4033 represent two structurally distinct non-steroidal selective androgen receptor modulators. Both have been investigated for their ability to interact with androgen receptors while generating tissue-dependent experimental responses. However, belonging to the same pharmacological category does not mean that their receptor interactions, concentration-response relationships or downstream transcriptional profiles are identical.\u003c\/p\u003e\n\u003cp\u003eYK-11 creates an additional research dimension. Although it demonstrates androgen-receptor-associated activity, its chemical structure differs substantially from conventional non-steroidal SARMs. Experimental cellular research has also generated interest in YK-11's relationship with myogenic differentiation and follistatin-associated expression.\u003c\/p\u003e\n\u003cp\u003eFollistatin participates in signalling involving members of the TGF-β superfamily, which has contributed to discussion of YK-11 within myostatin-related research. However, cellular observations involving follistatin should not be interpreted as proof that YK-11 directly blocks myostatin or guarantees a particular tissue response.\u003c\/p\u003e\n\u003cp\u003eThe three compounds therefore provide a framework for investigating multiple aspects of androgen-receptor and myogenic biology within one research theme. RAD-140 and LGD-4033 provide conventional non-steroidal SARM comparison points, while YK-11 introduces a structurally different androgen-receptor-associated compound with additional preliminary myogenic research interest.\u003c\/p\u003e\n\u003cp\u003eThe combination does not establish synergy between the compounds. Appropriate investigation should instead maintain compound-specific controls and distinguish receptor pharmacology, experimental observations and hypotheses requiring further evidence.\u003c\/p\u003e\n\u003ch2\u003e\u003c\/h2\u003e\n\u003ch2\u003eRAD-140 (Testolone) 50×15mg\u003c\/h2\u003e\n\u003cp\u003eRAD-140, commonly known as Testolone, is a synthetic non-steroidal selective androgen receptor modulator developed for experimental investigation of androgen-receptor signalling and tissue-selective biological responses. Its classification places it within the genuine SARM research category alongside compounds such as LGD-4033 and MK-2866, although each molecule possesses its own chemical structure and pharmacological characteristics.\u003c\/p\u003e\n\u003cp\u003eThe androgen receptor belongs to the nuclear-receptor family and functions as a ligand-regulated transcription factor. Interaction with an appropriate ligand can alter receptor conformation and influence subsequent co-regulator recruitment, DNA interactions and expression of androgen-responsive genes.\u003c\/p\u003e\n\u003cp\u003eRAD-140 research has examined whether a non-steroidal ligand can produce selective patterns of androgen-receptor activity across different experimental tissues and models. This tissue-selectivity principle is central to the wider scientific rationale behind SARM development.\u003c\/p\u003e\n\u003cp\u003eHowever, selective does not mean that activity is restricted to a single tissue, nor does it establish a particular experimental outcome. Receptor expression, concentration, exposure duration, cellular environment and the endpoints selected for analysis can all influence observations.\u003c\/p\u003e\n\u003cp\u003eWithin the Advanced Myogenic Signalling Research Set, RAD-140 provides one of the two conventional non-steroidal SARM components. Its androgen-receptor-associated research can be considered alongside LGD-4033, another structurally distinct selective androgen receptor modulator.\u003c\/p\u003e\n\u003cp\u003eYK-11 then expands the comparison beyond conventional non-steroidal SARM pharmacology by introducing a structurally different compound associated with both androgen-receptor activity and preliminary myogenic research questions.\u003c\/p\u003e\n\u003cp\u003eRAD-140 therefore contributes an important reference point for comparative androgen-receptor investigation within this three-compound set. Rather than assuming identical behaviour between all three molecules, researchers can examine compound-specific responses within a common experimental framework while retaining the individual pharmacological identity of Testolone.\u003c\/p\u003e\n\u003ch2\u003e\n\u003cbr\u003eLGD-4033 (Ligandrol) 50×15mg\u003c\/h2\u003e\n\u003cp\u003eLGD-4033, commonly known as Ligandrol, is a synthetic non-steroidal selective androgen receptor modulator developed for research into androgen-receptor signalling and tissue-selective pharmacology. It has a comparatively established research history within the SARM category and provides a useful reference compound for investigating selective androgen-receptor modulation.\u003c\/p\u003e\n\u003cp\u003eLike RAD-140, LGD-4033 interacts with the androgen receptor, a nuclear receptor capable of regulating transcription following ligand binding. However, sharing a receptor target does not make LGD-4033 and RAD-140 equivalent. Differences in molecular structure can influence receptor interaction, pharmacokinetic characteristics and experimentally observed downstream responses.\u003c\/p\u003e\n\u003cp\u003eLGD-4033 research has included controlled investigation extending beyond basic receptor-binding experiments, contributing to its position as one of the better-characterised selective androgen receptor modulators. These studies have helped researchers investigate the relationship between androgen-receptor modulation and various tissue-associated experimental endpoints.\u003c\/p\u003e\n\u003cp\u003eWithin the Advanced Myogenic Signalling Research Set, LGD-4033 provides the second conventional non-steroidal SARM component. This creates a useful comparison with RAD-140 because researchers can consider two different molecules developed around the same broad principle of selective androgen-receptor modulation.\u003c\/p\u003e\n\u003cp\u003eYK-11 then provides a contrasting third component. Its steroidal structure and additional experimental interest surrounding myogenic differentiation distinguish it from both Ligandrol and Testolone.\u003c\/p\u003e\n\u003cp\u003eThe resulting research framework therefore extends beyond simply grouping three commercially recognised compounds. LGD-4033 can be investigated independently, compared directly with RAD-140 and then considered alongside the different structural and experimental characteristics of YK-11.\u003c\/p\u003e\n\u003cp\u003eThis approach preserves compound-specific interpretation while allowing the shared androgen-receptor theme connecting the three molecules to form the basis of controlled comparative laboratory research.\u003c\/p\u003e\n\u003ch2\u003e\n\u003cbr\u003eYK-11 (Myostine) 50×15mg\u003c\/h2\u003e\n\u003cp\u003eYK-11, commonly referred to as Myostine within the research-compound market, is an experimental androgen-receptor-associated compound that occupies an unusual position within the wider SARM category. Although frequently grouped with selective androgen receptor modulators, its steroidal structure distinguishes it from non-steroidal compounds such as RAD-140 and LGD-4033.\u003c\/p\u003e\n\u003cp\u003eExperimental research has demonstrated androgen-receptor-associated activity, but YK-11 has attracted particular attention because of cellular research examining myogenic differentiation and follistatin-associated expression.\u003c\/p\u003e\n\u003cp\u003eFollistatin is a regulatory protein involved in biological pathways associated with members of the transforming growth factor-beta superfamily. Because this signalling network includes pathways involving myostatin, YK-11 has become widely discussed in relation to myostatin-associated research.\u003c\/p\u003e\n\u003cp\u003eThat interpretation requires significant caution. Experimental evidence showing changes in follistatin expression under specific cellular conditions does not establish that YK-11 directly inhibits myostatin or produces predetermined effects across different biological systems. Its evidence base is also much smaller than those of better-characterised SARM research compounds.\u003c\/p\u003e\n\u003cp\u003eThis makes YK-11 particularly interesting within the Advanced Myogenic Signalling Research Set. RAD-140 and LGD-4033 provide two conventional non-steroidal selective androgen receptor modulators, whereas YK-11 introduces a structurally different androgen-receptor-associated compound with additional preliminary research questions surrounding myogenic signalling.\u003c\/p\u003e\n\u003cp\u003eResearchers can therefore investigate common androgen-receptor-associated endpoints while separately considering YK-11-specific markers and hypotheses.\u003c\/p\u003e\n\u003cp\u003eYK-11 should not be treated as simply another interchangeable SARM within the set. Its structural characteristics, evidence limitations and specialised research history are precisely what differentiate it from RAD-140 and LGD-4033 and create the broader comparative value of this triple-compound research format.\u003c\/p\u003e\n\u003ch3\u003e\n\u003cbr\u003eExplore Related Research Compounds\u003c\/h3\u003e\n\u003cp\u003eContinue exploring related androgen-receptor and myogenic research compounds from the BioPlex SARMs capsule range.\u003c\/p\u003e\n\u003cp\u003e\u003ca title=\"RAD-140 Testolone | Research SARM Capsules | BioPlex UK\" rel=\"noopener\" class=\"decorated-link\" href=\"https:\/\/bioplexpeptides.co.uk\/products\/rad-140-tesolone-br-50x15mg\"\u003eView RAD-140 Testolone 50×15mg Research Capsules ⟶\u003c\/a\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ca title=\"LGD-4033 Ligandrol | Research SARM Capsules | BioPlex UK\" rel=\"noopener\" class=\"decorated-link\" href=\"https:\/\/bioplexpeptides.co.uk\/collections\/sarms?utm_source=chatgpt.com\"\u003eExplore LGD-4033 Ligandrol 50×15mg Research Capsules ⟶\u003c\/a\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ca title=\"YK-11 Myostine | Androgen \u0026amp; Myogenic Research Compound | BioPlex UK\" rel=\"noopener\" class=\"decorated-link\" href=\"https:\/\/bioplexpeptides.co.uk\/collections\/sarms?utm_source=chatgpt.com\"\u003eExplore YK-11 Myostine 50×15mg Research Capsules ⟶\u003c\/a\u003e\u003c\/p\u003e\n\u003ch3\u003e\n\u003cbr\u003eExplore BioPlex Research Information\u003c\/h3\u003e\n\u003cp\u003eAccess BioPlex SARMs guidance, compound classification and the complete research product range.\u003c\/p\u003e\n\u003cp\u003e\u003ca title=\"Complete SARMs UK Research Compound Guide 2026 | BioPlex Peptides\" rel=\"noopener\" class=\"decorated-link\" href=\"https:\/\/bioplexpeptides.co.uk\/blogs\/sarms-research-articles-bioplex-peptides-uk\/science-research-studies-complete-guide-to-sarms-uk-research-compounds-explained-for-2026?utm_source=chatgpt.com\"\u003eRead the Complete SARMs UK Research Compound Guide ⟶\u003c\/a\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ca title=\"SARMs Research Compounds UK | BioPlex Peptides\" rel=\"noopener\" class=\"decorated-link\" href=\"https:\/\/bioplexpeptides.co.uk\/collections\/sarms?utm_source=chatgpt.com\"\u003eExplore the BioPlex SARMs Research Range ⟶\u003c\/a\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ca title=\"All Research Products UK | Peptides, SARMs \u0026amp; Solutions | BioPlex Peptides\" rel=\"noopener\" class=\"decorated-link\" href=\"https:\/\/bioplexpeptides.co.uk\/collections\/all-products?utm_source=chatgpt.com\"\u003eView All BioPlex Research Products ⟶\u003c\/a\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003c\/h3\u003e\n\u003ch3\u003eExplore Related Research Articles\u003c\/h3\u003e\n\u003cp\u003eContinue your research with BioPlex articles covering selective androgen receptor modulators, androgen-receptor signalling and related research pathways.\u003c\/p\u003e\n\u003cp\u003e\u003ca title=\"RAD-140 Testolone Research Overview | BioPlex Peptides\" rel=\"noopener\" class=\"decorated-link\" href=\"https:\/\/bioplexpeptides.co.uk\/blogs\/sarms-research-articles-bioplex-peptides-uk\/rad-140-testolone-research-overview\"\u003eRead the RAD-140 Testolone Research Overview ⟶\u003c\/a\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ca title=\"RAD-140 LGD-4033 YK-11 SARMs Research Guide | BioPlex Peptides\" rel=\"noopener\" class=\"decorated-link\" href=\"https:\/\/bioplexpeptides.co.uk\/blogs\/sarms-research-articles-bioplex-peptides-uk\/science-research-studies-complete-guide-to-sarms-uk-research-compounds-explained-for-2026?utm_source=chatgpt.com\"\u003eRead the Complete SARMs UK Research Compound Guide ⟶\u003c\/a\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ca title=\"SARMs Research Articles | BioPlex Peptides UK\" rel=\"noopener\" class=\"decorated-link\" href=\"https:\/\/bioplexpeptides.co.uk\/blogs\/sarms-research-articles-bioplex-peptides-uk?utm_source=chatgpt.com\"\u003eExplore All BioPlex SARMs Research Articles ⟶\u003c\/a\u003e\u003c\/p\u003e\n\u003ch2\u003e\u003c\/h2\u003e\n\u003ch2\u003eDisclaimer\u003c\/h2\u003e\n\u003cp\u003e\u003ca title=\"Legal Notice | BioPlex Peptides UK\" rel=\"noopener\" class=\"decorated-link\" href=\"https:\/\/bioplexpeptides.co.uk\/policies\/legal-notice?utm_source=chatgpt.com\"\u003eFor research purposes only. Not for human consumption.\u003c\/a\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"BioPlex Peptides","offers":[{"title":"Default Title","offer_id":58753434845568,"sku":null,"price":125.99,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0991\/6783\/0400\/files\/MaximumMyogenicResearchSet.png?v=1787397676","url":"https:\/\/bioplexpeptides.co.uk\/sv\/products\/rad-140-lgd-4033-yk-11","provider":"BioPlexPeptides.co.uk","version":"1.0","type":"link"}